SEC Company Response from Apyx Medical (APYX) — May 16, 2018
Apyx Medical Corp
Date: May 16, 2018 · CIK: 0000719135 · Accession: 0000719135-18-000037
AI Filing Summary & Sentiment
File numbers found in text: 333-224677
Show Raw Text
CORRESP 1 filename1.htm Document CORRESP May 16, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 (File No. 333-224677) of Bovie Medical Corporation (the “Registrant”) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, and on behalf of the Registrant, we hereby request that the effectiveness of the above-captioned Registration Statement (the “Registration Statement”) be accelerated so that such Registration Statement will become effective on Wednesday, May 16, 2018 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable. The Registrant hereby authorizes Adam P. Silvers, of Ruskin Moscou Faltischek, P.C., to orally modify or withdraw this request for acceleration. We request that we be notified of such effectiveness by a telephone call to Mr. Silvers at (516) 663-6519, or in his absence Michael S. Williams, of Ruskin Moscou Faltischek, P.C., at (516) 663-6657. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of such Registration Statement be sent to Ruskin Moscou Faltischek, P.C., attention: Adam P. Silvers, via email at asilvers@rmfpc.com. Very truly yours, BOVIE MEDICAL CORPORATION By: /s/ JAY D. EWERS Name: Title: Jay D. Ewers Chief Financial Officer 763495